

## First time human-on-a-chip predicts in vivo results based on in vitro model

July 3 2019



Credit: CC0 Public Domain

Hesperos Inc., pioneers of the "human-on-a-chip" in vitro system has



announced the use of its innovative multi-organ model to successfully measure the concentration and metabolism of two known cardiotoxic small molecules over time, to accurately describe the drug behavior and toxic effects in vivo. The findings further support the potential of bodyon-a-chip systems to transform the drug discovery process.

In a study published in *Nature Scientific Reports*, in collaboration with AstraZeneca, Hesperos described how they used a pumpless heart model and a heart:<u>liver</u> system to evaluate the temporal pharmacokinetic/pharmacodynamic (PKPD) relationship for terfenadine, an antihistamine that was banned due to toxic cardiac effects, as well as determine its mechanism of toxicity.

The study found there was a time-dependent, <u>drug</u>-induced response in the heart model. Further experiments were conducted, adding a metabolically competent liver module to the Hesperos Human-on-a-Chip system to observe what happened when terfenadine was converted to fexofenadine. By doing so, the researchers were able to determine the driver of the pharmacodynamic (PD) effect and develop a mathematical model to predict the effect of terfenadine in preclinical species. This is the first time an in vitro human-on-a-chip system has been shown to predict in vivo outcomes, which could be used to predict clinical trial outcomes in the future.

"The ability to examine PKPD relationships in vitro would enable us to understand compound behavior prior to in vivo testing, offering significant cost and time savings," said Dr. Shuler, President and CEO, Hesperos, Inc and Professor Emeritus, Cornell University. "We are excited about the potential of this technology to help us ensure that potential new drug candidates have a higher probability of success during the clinical trial process."

Understanding the inter-relationship between pharmacokinetics (PK),



the drug's time course for absorption, distribution, metabolism and excretion, and PD, the biological effect of a drug, is crucial in drug discovery and development. Scientists have learned that the maximum drug effect is not always driven by the peak drug concentration. In some cases, time is a critical factor influencing drug effect, but often this concentration-effect-time relationship only comes to light during the advanced stages of the preclinical program. In addition, often the data cannot be reliably extrapolated to humans.

"It is costly and time consuming to discover that potential drug candidates may have poor therapeutic qualities preventing their onward progression," said James Hickman, Chief Scientist at Hesperos and Professor at the University of Central Florida. "Being able to define this during early drug discovery will be a valuable contribution to the optimization of potential new drug candidates."

As demonstrated with the terfenadine experiment, the PKPD modelling approach was critical for understanding both the flux of compound between compartments as well as the resulting PD response in the context of dynamic exposure profiles of both parent and metabolite, as indicated by Dr. Shuler.

In order to test the viability of their system in a real-world drug discovery setting, the Hesperos team collaborated with scientists at AstraZeneca, to test one of their failed <u>small molecules</u>, known to have a CV risk.

One of the main measurements used to assess the electrical properties of the heart is the QT interval, which approximates the time taken from when the cardiac ventricles start to contract to when they finish relaxing. Prolongation of the QT interval on the electrocardiogram can lead to a fatal arrhythmia known as Torsade de Pointes. Consequently, it is a mandatory requirement prior to first-in-human administration of



potential new drug candidates that their ability to inhibit the hERG channel (a biomarker for QT prolongation) is investigated.

In the case of the AstraZeneca molecule, the molecule was assessed for hERG inhibition early on, and it was concluded to have a low potential to cause in vivo QT prolongation up to 100  $\mu$ M. In later pre-clinical testing, the QT interval increased by 22% at a concentration of just 3  $\mu$ M. Subsequent investigations found that a major metabolite was responsible. Hesperos was able to detect a clear PD effect at concentrations above 3  $\mu$ M and worked to determine the mechanism of toxicity of the molecule.

The ability of these systems to assess cardiac function non-invasively in the presence of both parent molecule and metabolite over time, using multiplexed and repeat drug dosing regimes, provides an opportunity to run long-term studies for chronic administration of drugs to study their potential <u>toxic effects</u>.

Hesperos, Inc. is the first company spun out from the Tissue Chip Program at NCATS (National Center for Advancing Translational Sciences), which was established in 2011 to address the long timelines, steep costs and high failure rates associated with the drug development process. Hesperos currently is funded through NCATS' Small Business Innovation Research program to undertake these studies and make tissue chips technology available as a service based company.

"The application of tissue chip technology in drug testing can lead to advances in predicting the potential effects of candidate medicines in people," said Danilo Tagle, Ph.D., associate director for special initiatives at NCATS.

**More information:** Christopher W. McAleer et al, On the potential of in vitro organ-chip models to define temporal pharmacokinetic-



pharmacodynamic relationships, *Scientific Reports* (2019). DOI: 10.1038/s41598-019-45656-4

## Provided by Hesperos

Citation: First time human-on-a-chip predicts in vivo results based on in vitro model (2019, July 3) retrieved 3 May 2024 from https://medicalxpress.com/news/2019-07-human-on-a-chip-vivo-results-based-vitro.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.